Zheng Xing Xing Ye Ri Bao·2025-11-17 08:49Market Overview - The biopharmaceutical sector experienced a decline of 1.94% on November 17, with Kexing Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Bohui Innovation: Closed at 8.00, up 2.56% with a trading volume of 824,300 shares [1] - ST Weiming: Closed at 8.31, up 2.21% with a trading volume of 60,800 shares [1] - Major decliners included: - Kexing Pharmaceutical: Closed at 34.59, down 7.88% with a trading volume of 53,300 shares [2] - Jinwei: Closed at 26.05, down 7.06% with a trading volume of 123,100 shares [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 1.211 billion yuan from institutional investors, while retail investors contributed a net inflow of 893 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Wanzhe Co.: Net outflow of 37.20 million yuan from institutional investors [3] - Olin Bio: Net inflow of 13.81 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different companies within the sector [3]